News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,900 Results
Type
Article (39144)
Company Profile (283)
Press Release (648473)
Section
Business (203900)
Career Advice (1996)
Deals (35372)
Drug Delivery (89)
Drug Development (80847)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344640)
Policy (32450)
Tag
Academia (2530)
Alliances (49183)
Alzheimer's disease (1257)
Approvals (16049)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64693)
Collaboration (482)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110005)
Executive appointments (394)
FDA (16767)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16340)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20120)
Phase II (28493)
Phase III (21237)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21664)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Last 7 days (580)
Last 30 days (2325)
Last 365 days (35163)
2024 (35002)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46542)
2018 (35019)
2017 (32109)
2016 (31482)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28571)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37268)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79825)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,900 Results for "transmedics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - June 21, 2024
TransMedics Group, Inc. announced that on June 18, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 1,002 shares of its common stock and an aggregate of 657 restricted stock units to 1 employee, each as a material inducement for the employee’s entry into employment with TransMedics.
June 21, 2024
·
2 min read
Press Releases
TransMedics to Host Investor & Analyst Day on December 10, 2024
November 26, 2024
·
1 min read
Business
TransMedics Reports First Quarter 2024 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2024.
April 30, 2024
·
9 min read
Press Releases
TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 19, 2024
·
1 min read
Genetown
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 17, 2024
TransMedics Group, Inc. announced that on May 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted stock units to 8 employees, each as a material inducement for each employee’s entry into employment with TransMedics.
May 17, 2024
·
2 min read
Press Releases
TransMedics Reports Third Quarter 2024 Financial Results
October 29, 2024
·
10 min read
Business
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024.
April 16, 2024
·
1 min read
Business
TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024
October 15, 2024
·
1 min read
Business
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023.
February 26, 2024
·
10 min read
Business
TransMedics to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX) today announced that it will release financial results for the fourth quarter and full year 2023 after market close on Monday, February 26, 2024.
February 12, 2024
·
1 min read
1 of 68,790
Next
